Web Innovators, Pharma, Insurance and Government Converge to Speak at Health 2.0 Europe

6-7 April 2010, Paris, France.
Health 2.0 Europe, a conference dedicated to how Web 2.0 and social media are transforming healthcare systems in Europe, has finalized its agenda and speaker list. Encompassing all aspects of the healthcare chain, the interactive program will address healthcare on both country- and European-wide levels, with local experts from converging industries.

"Health 2.0 Europe will show that Europe is producing creative e-health solutions to address the diversity of its 23 languages and 27 markets," said Denise Silber, president of Basil Strategies, organizer of the Paris event with Health 2.0's founders, Matthew Holt and Indu Subaiya.

Three keynote speakers will present government's perspective on Health 2.0 and national IT strategies on health and wellness:

  • Morten Elbæk Petersen, sundhed.dk (Denmark)
  • Etienne Caniard, National Authority for Health (France)
  • Pieter Vos, Council for Public Health and Health Care (Netherlands)

Panel topics include:

  • Search and content
  • Patients online communities
  • Physician online communities
  • Health 2.0 tools
  • Pharma and Health 2.0
  • Hospitals, payers and Health 2.0
  • Looking ahead for Health 2.0

Panel participants include influential members of Europe's eHealth community from 12 countries (Belgium, France, Germany, Hungary, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland, and the UK). Panel structures will differ from traditional conference formats to encourage interactive participation. Speakers will perform a demo of their organization's 2.0 tool and discuss the impact of each tool nationally and in Europe. The agenda also features Launch, Health 2.0 Europe's segment for showcasing European eHealth start-ups.

For further information and registration, please visit:
http://www.health2con.com/paris2010

About Health 2.0 Europe
Health 2.0 Europe is the premier conference dedicated to how Web 2.0 and social media are transforming healthcare systems in Europe. The conference brings together professionals in the converging industries of healthcare, the internet, mobile applications and social media. Health 2.0 Europe is organized by pioneering experts from Europe and the U.S. with decades of combined experience in health- and Web- related business and consulting, Matthew Holt and Indu Subaiya, founders of Health 2.0 in San Francisco, and Denise Silber, president of Basil Strategies in Paris. Please visit www.health2con.com/paris2010 for more information.

Most Popular Now

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...